A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of GDC-0449 As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission.

Trial Profile

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of GDC-0449 As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Genentech
  • Most Recent Events

    • 02 Oct 2012 Results published in Clinical Cancer Research.
    • 25 Apr 2012 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 29 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top